GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Gross Profit

Gland Pharma (NSE:GLAND) Gross Profit : ₹34,916 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Gross Profit?

Gland Pharma's gross profit for the three months ended in Mar. 2024 was ₹9,381 Mil. Gland Pharma's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₹34,916 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Gland Pharma's gross profit for the three months ended in Mar. 2024 was ₹9,381 Mil. Gland Pharma's Revenue for the three months ended in Mar. 2024 was ₹15,375 Mil. Therefore, Gland Pharma's Gross Margin % for the quarter that ended in Mar. 2024 was 61.01%.

Gland Pharma had a gross margin of 61.01% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 7 years, the highest Gross Margin % of Gland Pharma was 61.64%. The lowest was 51.89%. And the median was 57.00%.


Gland Pharma Gross Profit Historical Data

The historical data trend for Gland Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Gross Profit Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial 14,697.57 19,317.63 22,749.28 19,391.74 34,916.34

Gland Pharma Quarterly Data
Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,201.70 7,557.90 8,518.60 9,459.16 9,380.68

Competitive Comparison of Gland Pharma's Gross Profit

For the Drug Manufacturers - General subindustry, Gland Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Gross Profit falls into.



Gland Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Gland Pharma's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=56647.22 - 21730.88
=34,916

Gland Pharma's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=15374.5 - 5993.82
=9,381

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹34,916 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Gland Pharma's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=9,381 / 15374.5
=61.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Gland Pharma  (NSE:GLAND) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Gland Pharma had a gross margin of 61.01% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Gland Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Gland Pharma (NSE:GLAND) Business Description

Traded in Other Exchanges
Address
Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines